Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Böttiger, BW; Arntz, HR; Chamberlain, DA; Bluhmki, E; Belmans, A; Danays, T; Carli, PA; Adgey, JA; Bode, C; Wenzel, V; TROICA Trial Investigators; European Resuscitation Council Study Group.
Thrombolysis during resuscitation for out-of-hospital cardiac arrest.
N Engl J Med. 2008; 359(25):2651-2662
Doi: 10.1056/NEJMoa070570
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Prause Gerhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Approximately 70% of persons who have an out-of-hospital cardiac arrest have underlying acute myocardial infarction or pulmonary embolism. Therefore, thrombolysis during cardiopulmonary resuscitation may improve survival. Methods: In a double-blind, multicenter trial, we randomly assigned adult patients with witnessed out-of-hospital cardiac arrest to receive tenecteplase or placebo during cardiopulmonary resuscitation. Adjunctive heparin or aspirin was not used. The primary end point was 30-day survival; the secondary end points were hospital admission, return of spontaneous circulation, 24-hour survival, survival to hospital discharge, and neurologic outcome. Results: After blinded review of data from the first 443 patients, the data and safety monitoring board recommended discontinuation of enrollment of asystolic patients because of low survival, and the protocol was amended. Subsequently, the trial was terminated prematurely for futility after enrolling a total of 1050 patients. Tenecteplase was administered to 525 patients and placebo to 525 patients; the two treatment groups had similar clinical profiles. We did not detect any significant differences between tenecteplase and placebo in the primary end point of 30-day survival (14.7% vs. 17.0%; P=0.36; relative risk, 0.87; 95% confidence interval, 0.65 to 1.15) or in the secondary end points of hospital admission (53.5% vs. 55.0%, P=0.67), return of spontaneous circulation (55.0% vs. 54.6%, P=0.96), 24-hour survival (30.6% vs. 33.3%, P=0.39), survival to hospital discharge (15.1% vs. 17.5%, P=0.33), or neurologic outcome (P=0.69). There were more intracranial hemorrhages in the tenecteplase group. Conclusions: When tenecteplase was used without adjunctive antithrombotic therapy during advanced life support for out-of-hospital cardiac arrest, we did not detect an improvement in outcome, in comparison with placebo. (ClinicalTrials.gov number, NCT00157261.).
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Cardiopulmonary Resuscitation - methods
- Chi-Square Distribution -
- Double-Blind Method -
- Female -
- Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use
- Follow-Up Studies -
- Heart Arrest - drug therapy Heart Arrest - mortality Heart Arrest - therapy
- Humans -
- Intracranial Hemorrhages - chemically induced
- Kaplan-Meier Estimate -
- Male -
- Middle Aged -
- Prospective Studies -
- Survival Rate -
- Thrombolytic Therapy -
- Tissue Plasminogen Activator - adverse effects Tissue Plasminogen Activator - therapeutic use
- Treatment Failure -